Evidence map›Paper›PMID 42049931›Full record

ArticleNature cancer2026

Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.

Chengyi Li, Fang Ke, Hongyi Zhao, Shuai Mao, Mahamadou Djibo, Linqi Huang, Miao He, Meilin Wang, Hanning Wen, Zhongwei Liu and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Chengyi LiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. chengyil@umich.edu.ORCID http://orcid.org/0000-0003-2378-6408
Fang KeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Hongyi ZhaoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Shuai MaoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Mahamadou DjiboDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Linqi HuangDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Miao HeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Meilin WangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Hanning WenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Zhongwei LiuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Zhixin YuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Zhihong QiDepartment of Immunology, Yale University, New Haven, CT, USA.
Ana R XavierDepartment of Biomedicine, University of Basel, Basel, Switzerland.
Minal NenwaniDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Bo WenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-8337-220X
Nicole PetersonDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Vaibhav SahaiDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-1892-1548
Deepak NagrathDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-8999-2282
Carrie L LucasDepartment of Immunology, Yale University, New Haven, CT, USA.
Matthias P WymannDepartment of Biomedicine, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-3349-4281
Wei GaoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. wgao21@central.uh.edu.ORCID http://orcid.org/0000-0002-5233-3734
Lawrence FongImmunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6428-428X
Duxin SunDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. duxins@umich.edu.ORCID http://orcid.org/0000-0002-6406-2126

Funding

University of Michigan (U-M) N035800
6 · The paper itself

Abstract

Both regulatory B (B

Indexed as

B-Lymphocytes, RegulatoryClass Ib Phosphatidylinositol 3-KinaseMembrane ProteinsMyeloid CellsPancreatic NeoplasmsAnimalsCell Line, TumorcGAS-STING Signaling PathwayFemaleHumansMiceMice, TransgenicProgrammed Cell Death 1 ReceptorSTING ProteinClass Ib Phosphatidylinositol 3-KinaseMembrane ProteinsPik3cg protein, mouseProgrammed Cell Death 1 ReceptorSting1 protein, mouseSTING Protein

Identifiers

PMID42049931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.